Hofseth BioCare ASA (HBC.OL)
NOK 2.1
(0.95%)
NOK 2.1
(0.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 112.89 Million NOK | 51.98% |
| 2022 | 74.28 Million NOK | -19.23% |
| 2021 | 91.97 Million NOK | 231.63% |
| 2020 | -69.86 Million NOK | -265.44% |
| 2019 | 42.23 Million NOK | 337.22% |
| 2018 | 9.65 Million NOK | -76.3% |
| 2017 | 40.75 Million NOK | -31.26% |
| 2016 | 59.28 Million NOK | -16.67% |
| 2015 | 71.14 Million NOK | -27.86% |
| 2014 | 98.62 Million NOK | 5.23% |
| 2013 | 93.72 Million NOK | 39.82% |
| 2012 | 67.03 Million NOK | 1234.24% |
| 2011 | 5.02 Million NOK | -15.12% |
| 2010 | 5.91 Million NOK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 140.43 Million NOK | 24.39% |
| 2024 Q2 | 144.16 Million NOK | 2.66% |
| 2023 Q3 | 81.83 Million NOK | -3.29% |
| 2023 Q4 | 112.89 Million NOK | 37.96% |
| 2023 FY | 112.89 Million NOK | 51.98% |
| 2023 Q1 | 78.17 Million NOK | 5.23% |
| 2023 Q2 | 84.61 Million NOK | 8.24% |
| 2022 Q1 | 105.03 Million NOK | 14.2% |
| 2022 FY | 74.28 Million NOK | -19.23% |
| 2022 Q4 | 74.28 Million NOK | 23.17% |
| 2022 Q3 | 60.31 Million NOK | -60.83% |
| 2022 Q2 | 153.96 Million NOK | 46.59% |
| 2021 Q2 | 15.93 Million NOK | 139.02% |
| 2021 FY | 91.97 Million NOK | 231.63% |
| 2021 Q1 | -40.83 Million NOK | 41.55% |
| 2021 Q3 | 54.63 Million NOK | 242.89% |
| 2021 Q4 | 91.97 Million NOK | 68.32% |
| 2020 Q2 | 83.07 Million NOK | 76.18% |
| 2020 Q1 | 47.15 Million NOK | 11.66% |
| 2020 FY | -69.86 Million NOK | -265.44% |
| 2020 Q3 | 118.55 Million NOK | 42.7% |
| 2020 Q4 | -69.86 Million NOK | -158.94% |
| 2019 Q3 | 28.41 Million NOK | -72.04% |
| 2019 FY | 42.23 Million NOK | 337.22% |
| 2019 Q1 | 89.24 Million NOK | 823.94% |
| 2019 Q4 | 42.23 Million NOK | 48.64% |
| 2019 Q2 | 101.62 Million NOK | 13.88% |
| 2018 Q1 | 42.23 Million NOK | 3.63% |
| 2018 FY | 9.65 Million NOK | -76.3% |
| 2018 Q4 | 9.65 Million NOK | 613.5% |
| 2018 Q2 | 64.01 Million NOK | 51.57% |
| 2018 Q3 | -1.88 Million NOK | -102.94% |
| 2017 Q2 | 14.93 Million NOK | 35654.76% |
| 2017 FY | 40.75 Million NOK | -31.26% |
| 2017 Q4 | 40.75 Million NOK | 282.65% |
| 2017 Q1 | -42 Thousand NOK | -100.07% |
| 2017 Q3 | 10.65 Million NOK | -28.67% |
| 2016 Q4 | 59.28 Million NOK | 31.78% |
| 2016 FY | 59.28 Million NOK | -16.67% |
| 2016 Q1 | 96.18 Million NOK | 35.19% |
| 2016 Q2 | 121.2 Million NOK | 26.02% |
| 2016 Q3 | 44.99 Million NOK | -62.88% |
| 2015 Q1 | 105.84 Million NOK | 7.32% |
| 2015 FY | 71.14 Million NOK | -27.86% |
| 2015 Q4 | 71.14 Million NOK | -35.86% |
| 2015 Q3 | 110.92 Million NOK | 20.08% |
| 2015 Q2 | 92.37 Million NOK | -12.73% |
| 2014 Q2 | 80.52 Million NOK | -17.45% |
| 2014 FY | 98.62 Million NOK | 5.23% |
| 2014 Q1 | 97.54 Million NOK | 4.07% |
| 2014 Q4 | 98.62 Million NOK | 14.87% |
| 2014 Q3 | 85.85 Million NOK | 6.63% |
| 2013 Q4 | 93.72 Million NOK | 10.2% |
| 2013 Q2 | 74.67 Million NOK | -17.1% |
| 2013 Q1 | 90.07 Million NOK | 34.38% |
| 2013 FY | 93.72 Million NOK | 39.82% |
| 2013 Q3 | 85.04 Million NOK | 13.9% |
| 2012 Q3 | 56.42 Million NOK | 78.79% |
| 2012 Q1 | 18.69 Million NOK | 272.2% |
| 2012 FY | 67.03 Million NOK | 1234.24% |
| 2012 Q2 | 31.55 Million NOK | 68.78% |
| 2012 Q4 | 67.03 Million NOK | 18.8% |
| 2011 Q4 | 5.02 Million NOK | -76.08% |
| 2011 Q3 | 21 Million NOK | 0.0% |
| 2011 FY | 5.02 Million NOK | -15.12% |
| 2010 FY | 5.91 Million NOK | 0.0% |
| 2010 Q4 | 5.91 Million NOK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arctic Bioscience AS | -77.55 Million NOK | 245.576% |
| Aqua Bio Technology ASA | -5.82 Million NOK | 2036.926% |
| ArcticZymes Technologies ASA | -237.27 Million NOK | 147.582% |
| BerGenBio ASA | -155.55 Million NOK | 172.58% |
| PCI Biotech Holding ASA | -40.86 Million NOK | 376.28% |
| Thor Medical ASA | -41.28 Million NOK | 373.469% |
| Ultimovacs ASA | -262.84 Million NOK | 142.953% |